Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293600 · ClinicalTrials.gov registry record · Phase 1
Rescue Pharmacotherapy for OSA
A Phase 1 study of Obstructive Sleep Apnea, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05293600 is a Phase 1 study of Obstructive Sleep Apnea that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 70 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05293600, a Phase 1 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of undertreated OSA. In this study, the investigators want to test the addition of a drug treatment to their regimen. Endotypes will be targeted pharmacologically with one of the following drugs: acetazolamide for a high loop gain, atomoxetine-plus-eszopiclone for poor pharyngeal muscle compensation, or trazodone for a low arousal threshold. This aim is expected to provide treatment strategies for rescuing non-responders to MAD or HGNS therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetazolamide
- DRUG Trazodone
- DRUG Atomoxetine and eszopiclone
Study Locations (1)
Massachusetts
- Sleep Disorders Research Program Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05293600
The ClinicalTrials.gov registry entry for NCT05293600 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (68% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05293600 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05293600 about?
NCT05293600 is a clinical study titled "Rescue Pharmacotherapy for OSA". Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of un...
What is the current status of trial NCT05293600?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-07-01. Estimated completion is 2026-10-30.
What conditions does trial NCT05293600 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT05293600?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG), Trazodone (DRUG), Atomoxetine and eszopiclone (DRUG).
Who is sponsoring clinical trial NCT05293600?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05293600 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
RECRUITING · Phase 1
-
DRonabinol Treatment of OSA
RECRUITING · Phase 1
-
Trazodone on OSA Endotypes
RECRUITING · Phase 1
-
Atomoxetine and DAW2022 on OSA Severity
RECRUITING · Phase 1
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Pharmacological Activation of HMN for OSA Aim 2
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.